DE19548812A1 - Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation - Google Patents

Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation

Info

Publication number
DE19548812A1
DE19548812A1 DE19548812A DE19548812A DE19548812A1 DE 19548812 A1 DE19548812 A1 DE 19548812A1 DE 19548812 A DE19548812 A DE 19548812A DE 19548812 A DE19548812 A DE 19548812A DE 19548812 A1 DE19548812 A1 DE 19548812A1
Authority
DE
Germany
Prior art keywords
hoe
medicament
manufacture
exchange inhibitor
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19548812A
Other languages
German (de)
English (en)
Inventor
Klaus Dr Wirth
Wolfgang Dr Scholz
Hans-Willi Dr Jansen
Hans Jochen Dr Lang
Joachim Dr Brendel
Heinz-Werner Dr Kleemann
Jan-Robert Dr Schwark
Andreas Dr Weichert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Priority to DE19548812A priority Critical patent/DE19548812A1/de
Priority to CA002241531A priority patent/CA2241531A1/en
Priority to EP96943956A priority patent/EP0869779A1/de
Priority to SK883-98A priority patent/SK88398A3/sk
Priority to IL12511496A priority patent/IL125114A0/xx
Priority to BR9612287-0A priority patent/BR9612287A/pt
Priority to CN96199403A priority patent/CN1207676A/zh
Priority to PCT/EP1996/005614 priority patent/WO1997024113A1/de
Priority to KR1019980704927A priority patent/KR19990076802A/ko
Priority to TR1998/01235T priority patent/TR199801235T2/xx
Priority to PL96327693A priority patent/PL327693A1/xx
Priority to HU9900807A priority patent/HUP9900807A3/hu
Priority to AU13720/97A priority patent/AU717247B2/en
Publication of DE19548812A1 publication Critical patent/DE19548812A1/de
Priority to MX9805141A priority patent/MX9805141A/es
Priority to NO982989A priority patent/NO982989L/no
Priority to CZ982021A priority patent/CZ202198DA3/cs
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60L—PROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L50/00—Electric propulsion with power supplied within the vehicle
    • B60L50/50—Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells
    • B60L50/60—Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells using power supplied by batteries
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60L—PROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L7/00—Electrodynamic brake systems for vehicles in general
    • B60L7/10—Dynamic electric regenerative braking
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60L—PROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L7/00—Electrodynamic brake systems for vehicles in general
    • B60L7/10—Dynamic electric regenerative braking
    • B60L7/16—Dynamic electric regenerative braking for vehicles comprising converters between the power source and the motor
    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01C—CONSTRUCTION OF, OR SURFACES FOR, ROADS, SPORTS GROUNDS, OR THE LIKE; MACHINES OR AUXILIARY TOOLS FOR CONSTRUCTION OR REPAIR
    • E01C19/00—Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving
    • E01C19/22—Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving for consolidating or finishing laid-down unset materials
    • E01C19/23—Rollers therefor; Such rollers usable also for compacting soil
    • E01C19/26—Rollers therefor; Such rollers usable also for compacting soil self-propelled or fitted to road vehicles
    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01C—CONSTRUCTION OF, OR SURFACES FOR, ROADS, SPORTS GROUNDS, OR THE LIKE; MACHINES OR AUXILIARY TOOLS FOR CONSTRUCTION OR REPAIR
    • E01C19/00—Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving
    • E01C19/22—Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving for consolidating or finishing laid-down unset materials
    • E01C19/23—Rollers therefor; Such rollers usable also for compacting soil
    • E01C19/28—Vibrated rollers or rollers subjected to impacts, e.g. hammering blows

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Transportation (AREA)
  • Power Engineering (AREA)
  • Civil Engineering (AREA)
  • Architecture (AREA)
  • Structural Engineering (AREA)
  • Sustainable Energy (AREA)
  • Sustainable Development (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE19548812A 1995-12-27 1995-12-27 Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation Withdrawn DE19548812A1 (de)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DE19548812A DE19548812A1 (de) 1995-12-27 1995-12-27 Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
PCT/EP1996/005614 WO1997024113A1 (de) 1995-12-27 1996-12-13 VERWENDUNG VON INHIBITOREN DES ZELLULÄREN Na+/H+-EXCHANGERS (NHE) ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR ATEMSTIMULATION
PL96327693A PL327693A1 (en) 1995-12-27 1996-12-13 Application of cellular na+/h+(nhe) ions exchanger inhibitors in production of a respiration stimulating drug
SK883-98A SK88398A3 (en) 1995-12-27 1996-12-13 Use of inhibitors of the cellular na+/h+ exchanger (nhe) for the preparation of a drug for respiratory stimulation
IL12511496A IL125114A0 (en) 1995-12-27 1996-12-13 Use of inhibitor of the cellular na+/h+ exchanger (nhe) for the production of a medicament for respiratory stimulation
BR9612287-0A BR9612287A (pt) 1995-12-27 1996-12-13 Emprego de inibidores de troca de na+ /h+ (nhe) celular para a preparação de um medicamento para estimular a respiração
CN96199403A CN1207676A (zh) 1995-12-27 1996-12-13 细胞Na+/H+交换器(NHE)抑制剂在制备呼吸刺激药物中的用途
CA002241531A CA2241531A1 (en) 1995-12-27 1996-12-13 Use of inhibitors of the cellular na+/h+ exchanger (nhe) for the preparation of a drug for respiratory stimulation
KR1019980704927A KR19990076802A (ko) 1995-12-27 1996-12-13 호흡 자극용 약제를 제조하기 위한 세포성 na+/h+ 교환기(nhe) 억제제의 용도
TR1998/01235T TR199801235T2 (xx) 1995-12-27 1996-12-13 �nhibit�rlerin solunum stim�lasyonuna y�nelik ila� �retiminde kullan�m�.
EP96943956A EP0869779A1 (de) 1995-12-27 1996-12-13 VERWENDUNG VON INHIBITOREN DES ZELLULÄREN Na?+ /H?+ -EXCHANGERS (NHE) ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR ATEMSTIMULATION
HU9900807A HUP9900807A3 (en) 1995-12-27 1996-12-13 Use of inhibitors of the cellular na+/h+exchanger (nhe) for the preparation of a drug for respiratory stimulation
AU13720/97A AU717247B2 (en) 1995-12-27 1996-12-13 Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for respiratory stimulation
MX9805141A MX9805141A (es) 1995-12-27 1998-06-24 Uso de inhibidores del intercambiador celular na+/h+ (nhe) para la preparacion de un farmaco para estimular la respiracion.
NO982989A NO982989L (no) 1995-12-27 1998-06-26 Anvendelse av inhibitorer av den cellulµre Na+/H+-utbytteren (NHE) for fremstilling av et medikament for respiratorstimulering
CZ982021A CZ202198DA3 (cs) 1995-12-27 2021-03-03 Použití inhibitorů výměny Na+/H+ k přípravě léčiva k léčení narušené stimulace dýchání

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19548812A DE19548812A1 (de) 1995-12-27 1995-12-27 Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation

Publications (1)

Publication Number Publication Date
DE19548812A1 true DE19548812A1 (de) 1997-07-03

Family

ID=7781474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19548812A Withdrawn DE19548812A1 (de) 1995-12-27 1995-12-27 Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation

Country Status (16)

Country Link
EP (1) EP0869779A1 (no)
KR (1) KR19990076802A (no)
CN (1) CN1207676A (no)
AU (1) AU717247B2 (no)
BR (1) BR9612287A (no)
CA (1) CA2241531A1 (no)
CZ (1) CZ202198DA3 (no)
DE (1) DE19548812A1 (no)
HU (1) HUP9900807A3 (no)
IL (1) IL125114A0 (no)
MX (1) MX9805141A (no)
NO (1) NO982989L (no)
PL (1) PL327693A1 (no)
SK (1) SK88398A3 (no)
TR (1) TR199801235T2 (no)
WO (1) WO1997024113A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923370B1 (en) * 1995-12-19 2005-11-16 Curapath AB Acetyl choline esterase inhibitors for treating and diagnosing sleep disordered breathing

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19945302A1 (de) * 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
DE10060292A1 (de) 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
MX2011007024A (es) 2008-12-31 2011-09-27 Aedelyx Inc Compuestos y metodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrogeno (nhe) en el tratamiento de trastornos asociados con retencion de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
PT2983667T (pt) 2013-04-12 2019-07-11 Ardelyx Inc Compostos e métodos de ligação ao nhe3 para inibir o transporte de fosfato
BR112017000691B1 (pt) 2014-07-25 2023-02-14 Taisho Pharmaceutical Co., Ltd Feniltetra-hidroisoquinolina substituído com heteroari-la, seu uso, medicamento, inibidores de nhe3, de absorção de sódio e de absorção de fósforo, promotor de secre-ção de água intestinal e fármaco profilático ou terapêu-tico para constipação
MX2019008170A (es) 2017-01-09 2020-02-07 Ardelyx Inc Compuestos útiles para tratar transtornos del tracto gastrointestinal.
KR20190128626A (ko) 2017-01-09 2019-11-18 알데릭스, 인코포레이티드 Nhe-매개 역수송의 저해제
UA126584C2 (uk) 2017-08-04 2022-11-02 Арделікс, Інк. Похідні гліцирретинової кислоти для лікування гіперкаліємії
AU2020218255A1 (en) 2019-02-07 2021-09-09 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0639573A1 (de) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
DE4337609A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4415873A1 (de) * 1994-05-05 1995-11-09 Hoechst Ag Substituierte bizyklische Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923370B1 (en) * 1995-12-19 2005-11-16 Curapath AB Acetyl choline esterase inhibitors for treating and diagnosing sleep disordered breathing

Also Published As

Publication number Publication date
EP0869779A1 (de) 1998-10-14
MX9805141A (es) 1998-10-31
NO982989D0 (no) 1998-06-26
SK88398A3 (en) 1999-03-12
PL327693A1 (en) 1998-12-21
AU1372097A (en) 1997-07-28
CN1207676A (zh) 1999-02-10
TR199801235T2 (xx) 1998-10-21
HUP9900807A3 (en) 2000-11-28
KR19990076802A (ko) 1999-10-15
CA2241531A1 (en) 1997-07-10
WO1997024113A1 (de) 1997-07-10
BR9612287A (pt) 2005-05-24
IL125114A0 (en) 1999-01-26
AU717247B2 (en) 2000-03-23
NO982989L (no) 1998-08-06
HUP9900807A2 (hu) 1999-07-28
CZ202198DA3 (cs) 1998-11-11

Similar Documents

Publication Publication Date Title
DE19548812A1 (de) Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
DE2810918C2 (de) Taurin-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
CH650926A5 (de) Antiparkinson-mittel.
DE2360332C2 (de) Die Verwendung von 1-Carnitin oder einem 1-Carnitinderivat oder eines Salzes davon bei der Behandlung spezieller Lungenkrankheiten
EP0245669B1 (de) Pharmazeutisches Präparat zur Verhütung der Schädigung lebender Zellen durch freie Radikale, beziehungsweise zur Erhöhung der Wirksamkeit von organischen Schwefelverbindungen und Verfahren zur Erhöhung der Lebensdauer isolierter Organe
DE3619426A1 (de) Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion
DE2759108A1 (de) Verwendung von alpha -mercapto-beta- aryl-acrylsaeuren bei der steigerung des zinkgehaltes im serum und im gewebe
DE3153623C2 (no)
DE3111593C2 (de) 3-Desoxy-3-[3-(2-chloräthyl)-3-nitrosoureido]-D-allopyranose, Verfahren zu ihrer Herstellung und diese Verbindung enthaltende Antitumormittel
DE3141970C2 (no)
DE1768575B2 (no)
CH634991A5 (de) Antibakterielles mittel fuer medizinische zwecke.
DE2448564C3 (de) Verwendung von heterocyclischen Carbonsäuren
EP0152860B1 (de) Verwendung von Cephemverbindungen zur Herstellung eines Arzneimittels für die Modulation des Immunsystems
AT368167B (de) Verfahren zur herstellung von neuen adenosintriphosphat (atp)-metallkomplexen
DE2760340C2 (no)
CH380098A (de) Verfahren zur Herstellung von neuen Benzolsulfonylbenzylharnstoffen
DE2101187C3 (de) Mittel zur Verabreichung an Geflügel und Schweine, um sie vor Pasteurella species zu schützen
AT211310B (de) Verfahren zur Herstellung von neuen 2-Sulfonamido-thiadiazol-Derivaten
Okada et al. Improvement of hemodynamics by oral pirbuterol in congestive heart failure. Iwasaki T, Matsuo H, Ko-bori K, et al. Jpn J Acute Med 1987; 11: 845-849. Hemodynamic changes were studied in eight pa-tients with congestive heart failure (77 to 88 years old)
AT142713B (de) Verfahren zur Herstellung von in Lösungen haltbaren Präparaten, die anaesthesierend wirkende und gefäßverengende Mittel enthalten.
DE1197082B (de) Verfahren zur Herstellung von p- bzw. m-Diisothiocyanato-cyclohexan und deren Derivaten
DE2221352C3 (de) 2- (5- Nitrof uryl- (2) -vinyl) -4-methyl-5acetylthiazol-Derivate und antimicrobenwirksame Mittel
Blomer et al. A summary of clinical phase II and phase III study results on ofloxacin (HOE 280) in Europe
DE3513391A1 (de) Neues nootropikum

Legal Events

Date Code Title Description
8130 Withdrawal